WallStreetZenWallStreetZen

NASDAQ: CMRX
Chimerix Inc Stock Forecast, Predictions & Price Target

Analyst price target for CMRX

Based on 1 analyst offering 12 month price targets for Chimerix Inc.
Min Forecast
$11.00+1,124.94%
Avg Forecast
$11.00+1,124.94%
Max Forecast
$11.00+1,124.94%

Should I buy or sell CMRX stock?

Based on 1 analyst offering ratings for Chimerix Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CMRX stock forecasts and price targets.

CMRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-01

1 of 1

Forecast return on equity

Is CMRX forecast to generate an efficient return?
Company
-25.06%
Industry
73.55%
Market
80.58%
CMRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CMRX forecast to generate an efficient return on assets?
Company
-22.48%
Industry
31.45%
CMRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CMRX earnings per share forecast

What is CMRX's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$0.85
Avg 2 year Forecast
-$1.03
Avg 3 year Forecast
-$0.68

CMRX revenue forecast

What is CMRX's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$27.5M+67,009.76%
Avg 2 year Forecast
$7.0M+16,973.17%
Avg 3 year Forecast
$70.0M+170,602.44%
CMRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CMRX revenue growth forecast

How is CMRX forecast to perform vs Biotechnology companies and vs the US market?
Company
1,036.37%
Industry
37.21%
Market
10.62%
CMRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CMRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CMRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CMRX$0.90$11.00+1,124.94%Buy
MAIA$3.65N/AN/A
PMVP$1.58$5.33+237.53%Strong Buy
ASMB$14.80N/AN/A
CGTX$1.98$9.80+394.95%Strong Buy

Chimerix Stock Forecast FAQ

Is Chimerix Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CMRX) stock is to Buy CMRX stock.

Out of 1 analyst, 0 (0%) are recommending CMRX as a Strong Buy, 1 (100%) are recommending CMRX as a Buy, 0 (0%) are recommending CMRX as a Hold, 0 (0%) are recommending CMRX as a Sell, and 0 (0%) are recommending CMRX as a Strong Sell.

If you're new to stock investing, here's how to buy Chimerix stock.

What is CMRX's earnings growth forecast for 2024-2026?

(NASDAQ: CMRX) Chimerix's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.78%.

Chimerix's earnings in 2024 is -$82,592,000.On average, 5 Wall Street analysts forecast CMRX's earnings for 2024 to be -$76,364,677, with the lowest CMRX earnings forecast at -$86,044,706, and the highest CMRX earnings forecast at -$66,326,127. On average, 5 Wall Street analysts forecast CMRX's earnings for 2025 to be -$92,318,799, with the lowest CMRX earnings forecast at -$102,178,088, and the highest CMRX earnings forecast at -$80,666,912.

In 2026, CMRX is forecast to generate -$60,724,259 in earnings, with the lowest earnings forecast at -$90,526,201 and the highest earnings forecast at -$13,444,485.

What is CMRX's revenue growth forecast for 2024-2026?

(NASDAQ: CMRX) Chimerix's forecast annual revenue growth rate of 1,036.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.21%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.62%.

Chimerix's revenue in 2024 is $41,000.On average, 2 Wall Street analysts forecast CMRX's revenue for 2024 to be $2,466,166,754, with the lowest CMRX revenue forecast at $2,243,436,447, and the highest CMRX revenue forecast at $2,688,897,060. On average, 2 Wall Street analysts forecast CMRX's revenue for 2025 to be $627,409,314, with the lowest CMRX revenue forecast at $448,149,510, and the highest CMRX revenue forecast at $806,669,118.

In 2026, CMRX is forecast to generate $6,273,017,581 in revenue, with the lowest revenue forecast at $1,246,303,787 and the highest revenue forecast at $12,678,149,638.

What is CMRX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CMRX) forecast ROA is -22.48%, which is lower than the forecast US Biotechnology industry average of 31.45%.

What is CMRX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CMRX price target, the average CMRX price target is $11.00, with the highest CMRX stock price forecast at $11.00 and the lowest CMRX stock price forecast at $11.00.

The Wall Street analyst predicted that Chimerix's share price could reach $11.00 by Mar 1, 2025. The average Chimerix stock price prediction forecasts a potential upside of 1,124.94% from the current CMRX share price of $0.90.

What is CMRX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: CMRX) Chimerix's current Earnings Per Share (EPS) is -$0.94. On average, analysts forecast that CMRX's EPS will be -$0.85 for 2024, with the lowest EPS forecast at -$0.96, and the highest EPS forecast at -$0.74. On average, analysts forecast that CMRX's EPS will be -$1.03 for 2025, with the lowest EPS forecast at -$1.14, and the highest EPS forecast at -$0.90. In 2026, CMRX's EPS is forecast to hit -$0.68 (min: -$1.01, max: -$0.15).

What is CMRX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CMRX) forecast ROE is -25.06%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.